US President, Joe Biden, has urged Americans not to panic about the new COVID-19 Omicron variant and said the United States was making contingency plans with pharmaceutical companies if new vaccines are needed, Reuters news agency reported on Tuesday.
Biden said the country would not go back to lockdowns to stop the spread of the Omicron variant and that he would lay out his strategy on Thursday for combating the pandemic over the winter.
The president said in remarks at the White House following a meeting with his COVID-19 team: "This variant is a cause for concern, not a cause for panic. We're going to fight and beat this new variant."
He also urged people to get vaccinated, get boosters and wear masks adding that it was inevitable that Omicron cases would emerge in the United States.
While Biden said he believed that existing vaccines would continue to protect against severe disease, he added that his administration was working with vaccine makers Pfizer (NYSE:PFE), Moderna (Nasdaq:MRNA) and Johnson & Johnson (NYSE:JNJ) to develop contingency plans.
President Biden also said he would direct the US Food and Drug Administration and the Centres for Disease Control and Prevention (CDC) to make those vaccines available quickly.
BeOne Medicines' sonrotoclax receives FDA Breakthrough Therapy Designation for MCL
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Oxford Biomedica expands US operations with acquisition of viral vector facility in North Carolina
DarioHealth and OneStep partner to integrate fall risk technology into digital health platform
Ananda Pharma achieves key Phase 1 milestone for MRX1 CBD program
Alvotech and Advanz Pharma announce EMA acceptance of AVT23 marketing application
Polarean expands Ascend Imaging partnership to boost US market reach